Is Famotidine an H2 Blocker?
Yes, famotidine is definitively a histamine-2 (H2) receptor antagonist (H2 blocker).
Mechanism of Action
Famotidine is a competitive inhibitor of histamine-2 (H2) receptors, with its primary pharmacologic activity being the inhibition of gastric acid secretion 1. The drug suppresses both the acid concentration and volume of gastric secretion 1.
Potency Compared to Other H2 Blockers
Famotidine is the most potent H2 receptor antagonist available:
- 20 to 50 times more potent than cimetidine on a weight basis 2
- Approximately 8 times more potent than ranitidine 3, 4
- Longer duration of action (10-12 hours) compared to other H2 antagonists 1, 2
Clinical Pharmacodynamics
The antisecretory effect of famotidine demonstrates the following characteristics:
- Onset of action: Within 30 minutes to 1 hour after oral administration 5, 1
- Peak effect: Occurs 1-3 hours after dosing 5, 1
- Duration: 10-12 hours of acid inhibition for standard doses 5, 1
- Nocturnal acid suppression: Evening doses of 20 mg and 40 mg inhibit nocturnal gastric acid secretion by 86% and 94%, respectively 1
Unique Pharmacologic Properties
Famotidine does not interact with the cytochrome P-450 hepatic enzyme system, eliminating drug-drug interactions through hepatic metabolism 5, 3. This distinguishes it from cimetidine and makes it particularly valuable in patients on multiple medications 6.
Famotidine has no antiandrogenic effects, unlike cimetidine which can occasionally cause such effects 5, 2.
Chemical Classification
Famotidine belongs to the guanidinothiazole structural class of H2 receptor antagonists, which differs from cimetidine (imidazole derivative) and ranitidine (basically substituted furan) 3, 4. The active ingredient is specifically described as a histamine-2 (H2) receptor antagonist with the empirical formula C8H15N7O2S3 1.
Clinical Relevance in Specific Populations
For patients on dual antiplatelet therapy (aspirin plus clopidogrel), famotidine is strongly preferred because it does not interfere with clopidogrel's antiplatelet activity through CYP2C19 inhibition, unlike proton pump inhibitors 7, 8, 6. The American College of Cardiology and American Heart Association specifically recommend famotidine over PPIs in this setting 6, 9.